Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Guardant Health

RFK Jr’s advisory panel overhaul stalled update on helping kids quit tobacco

US preventive services taskforce’s members have not issued binding recommendations since March 2025

The Guardian - US

Zydus Lifesciences ties up with Apollo Hospitals to offer Shield multi-cancer detection test

Zydus Lifesciences ties up with Apollo Hospitals to offer Shield multi-cancer detection test

Zydus Lifesciences has partnered with Apollo Hospitals to introduce the Shield multi-cancer detection test in India, made possible through an agreement with Guardant Health. This innovative blood test can identify signals for multiple cancer types in individuals aged 45 and above. The collaboration aims to enhance early cancer detection and…

The Economic Times

Steven Spielberg donates $25,000 to James Van Der Beek fundraiser for late actor's family

Steven Spielberg donates $25,000 to James Van Der Beek fundraiser for late actor's family

Iconic director Steven Spielberg and his wife Kate Capshaw have donated $25,000 to a GoFundMe support late actor James Van Der Beek's family.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Guardant Health Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Earnings

Guardant Health, Inc. (NASDAQ:GH) reported better-than-expected second-quarter financial results and raised its FY25 sales guidance above estimates on Wednesday.

Cathie Wood's Ark Invest Offloads Meta, Loads Up On Teradyne, Caris Life Sciences

On Friday, Cathie Wood-led Ark Invest made significant trades involving Teradyne Inc. (NASDAQ:TER), Meta Platforms Inc. (NASDAQ:META), Caris Life Sciences Inc. (NASDAQ:CAI) and Guardant Health Inc. (NASDAQ:GH).

4 Healthcare Stocks With Massive Gains—and More to Come

Healthcare is the top industry of 2025 so far. These healthcare companies have seen 30% increases in share prices since the beginning of the year.

Simple blood tests could be the future of cancer diagnosis

Blood tests that detect early cancer are coming to market. Could they lead to earlier diagnosis and treatment?

inkl

Read news from The Economist, FT, and more,
with one subscription

Deciphering Disruption: Inside Cathie Wood's Latest Plays

Deciphering Disruption: Inside Cathie Wood's Latest Plays

Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies.

A simple blood test can detect colorectal cancer early, study finds

A simple blood test can detect colorectal cancer early, study finds

At a time when colorectal cancer is rising, researchers say a blood test can detect 83% of people with the disease. If the FDA approves it the test would be another screening tool for early detection.

New Blood Test Shows Promise For Colon Cancer Screening

New Blood Test Shows Promise For Colon Cancer Screening

Learn about promising advancements in colon cancer screening methods, including new blood tests and improved stool tests, offering hope for increased early...

A Hidden AI Stock to Add to Your Portfolio

A Hidden AI Stock to Add to Your Portfolio

Many AI techniques are already being used in healthcare, where the highest degree of accuracy is required. One such area is oncology testing and the cancer research programs of Guardant Health.

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

10 Biggest Price Target Changes For Monday

10 Biggest Price Target Changes For Monday

Morgan Stanley cut Guardant Health, Inc. (NASDAQ: GH) price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in pre-market trading.

What 6 Analyst Ratings Have To Say About Guardant Health

What 6 Analyst Ratings Have To Say About Guardant Health

Over the past 3 months, 6 analysts have published their opinion on Guardant Health (NASDAQ:GH) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Get all your
news in one place.

100's of premium titles.
One news app.

Guardant Health's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q4, Guardant Health's (NASDAQ:GH) reported sales totaled $108.11 million. Despite a 32.75% increase in earnings, the company posted a loss of $72.31 million.

10 Biggest Price Target Changes For Thursday

SVB Leerink lowered Guardant Health, Inc. (NASDAQ: GH) price target from $170 to $140. Guardant Health shares dropped 5.7% to $56.22 in pre-market trading.

Recap: Guardant Health Q4 Earnings

Guardant Health (NASDAQ:GH) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:03 PM. Here's what investors need to know about the announcement.

1

People

206,268 stories

Robert F. Kennedy Jr

Steven Spielberg

James Van Der Beek

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

404,537 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play